English
Regional settings| Spread | 0.06 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 3.36 |
| Open | 3.28 |
| 1-Year Change | 51.85% |
| Day's Range | 3.2 - 3.33 |
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
BRIEF: For the nine months ended 30 September 2021, Tempest Therapeutics Inc revenues was not reported. Net loss decreased 29% to $20.5M. Lower net loss reflects Research and development - Balancing decrease of 23% to $12.2M (expense), Other general and administrative decrease of 32% to $6.6M (expense), Stock-based Compensation in SGA decrease of 75% to $600K (expense).
Common Stock $.001 par, 11/12, 100M auth., 14,262,276 issd., Insider Own approx.1%.
